Kyobo Life Insurance Launches Hybrid Underwriting Health Plan for Chronic Disease Patients
Kyobo Life Insurance has introduced South Korea’s first health insurance product combining general and simplified underwriting processes, addressing rising chronic disease costs in the nation’s aging population, according to company officials.
South Korea’s Aging Population Drives Insurance Innovation
With 20% of South Koreans aged 65 or older, the nation faces growing healthcare challenges. The Korea Disease Control and Prevention Agency reported 13 million hypertension patients and 6 million diabetes cases as of 2023, with 50% of those over 50 affected by chronic conditions.
Chronic disease medical costs reached 90 trillion won ($73 billion) in 2023, accounting for 80.3% of total healthcare expenditures, according to the Ministry of Health and Welfare. These figures have prompted insurers to reevaluate traditional underwriting models.
New Product Addresses Pricing Inefficiencies
Kyobo’s “K-Ready Health Insurance (Non-dividend, Hybrid Underwriting)” allows policyholders to apply different underwriting methods to specific coverage components. This approach contrasts with previous “simplified underwriting” products that applied uniform pricing rules across all benefits.
“By separating underwriting requirements, customers can maintain standard premiums for non-related coverage while only applying simplified terms to relevant benefits,” explained Kyobo Life spokesperson Kim Min-jun. “This reduces unnecessary cost burdens.”
Key Features and Cost Savings
The product offers 42 specialized coverage options, including:
- Cancer diagnosis and treatment (including advanced therapies like targeted drug treatment)
- Cerebrovascular and cardiovascular disease protection
- Surgical and hospitalization coverage for common conditions
Model calculations show a 16.2% premium reduction for a 40-year-old hypertension patient opting for standard underwriting for cancer coverage while using simplified terms for cardiovascular benefits, according to Kyobo’s actuarial analysis.
Expanded Access for Pre-Existing Conditions
The product enables coverage for individuals previously excluded due to health history. For example, those with a history of surgery or hospitalization can now access critical illness benefits through simplified underwriting.
It also includes a “no-claim refund” structure and a 50% premium waiver for policyholders developing a severe disability requiring long-term care, as defined by the National Health Insurance Service.
Market Context and Industry Response
This development follows a 2023 report by the Korean Insurance Development Institute showing 42% of South Koreans with chronic diseases face insurance affordability issues. The new product aligns with the Financial Supervisory Service’s 2024 guidelines encouraging innovative underwriting models.
Industry analysts note this could set a precedent for other insurers. “This approach balances risk management with consumer needs,” said Dr. Park Soo-jin, a healthcare economics professor at Seoul National University. “It may influence future regulatory frameworks.”
Eligibility and Coverage Details
The product is available to individuals aged 15-76, with coverage until age 100. Policyholders can choose premium payment terms from 10 to 30 years. Key benefits include:
- 100% death benefit coverage until age 100
- Cancer-specific coverage with 16 advanced treatment options
- Comprehensive cardiovascular disease protection including stroke and heart attack coverage
Customers with pre-existing conditions can still access critical illness benefits through the simplified underwriting component, according to Kyobo’s product documentation.
Industry Implications
This innovation comes as South Korea’s insurance market faces pressure from demographic shifts. The Korea Insurance Association reported a 12% increase in health insurance applications from individuals with chronic conditions in 2024.
Analysts suggest this model could reduce the 28% of South Koreans who currently lack adequate health insurance coverage, according to a 2023 Korea Institute for Health and Social Affairs survey.